A Survey of Adults and Children With Allergic Rhinoconjunctivitis and Physicians Who Administer Immunotherapy (MK-7243-021)
This study has been completed.
Sponsor:
Merck
Information provided by (Responsible Party):
Merck
ClinicalTrials.gov Identifier:
NCT01535118
First received: February 14, 2012
Last updated: June 21, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will gather information on allergic rhinoconjunctivitis from questionnaires completed by adults and children and physicians who administer immunotherapy (IT).
| Condition |
|---|
|
Allergic Rhinoconjunctivitis |
| Study Type: | Observational |
| Study Design: | Observational Model: Ecologic or Community Time Perspective: Prospective |
| Official Title: | National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America |
Resource links provided by NLM:
Further study details as provided by Merck:
Primary Outcome Measures:
- The Proportion of Participants Who Experience Daily Symptoms, Work or Activity Impairment due to Allergic Rhinoconjunctivitis [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
- The Proportion of Participants Prescribed Medications for Allergic Rhinoconjunctivitis [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
- The Proportion of Participants Advised on Immunotherapy [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
- The Proportion of Participants on Immunotherapy that Require Supplemental Allergy Medications [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The Proportion of Participants on Immunotherapy With a Co-morbid Condition [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 2765 |
| Study Start Date: | January 2012 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Adults and Children with ARC
Adults and Children with ARC who complete the questionnaire.
|
|
Physicians Who Administer Immunotherapy
Physicians who administer immunotherapy and complete the questionnaire.
|
Eligibility| Ages Eligible for Study: | 5 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Adults and children with ARC in the United States. Physicians who administer immunotherapy in the United States.
Criteria
Inclusion Criteria:
- Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies
- 5 years of age or older
- Have a telephone
Exclusion Criteria:
- If less than 18 years old and there is no adult available that is knowledgeable about the participant's health
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Merck |
| ClinicalTrials.gov Identifier: | NCT01535118 History of Changes |
| Other Study ID Numbers: | 7243-021 |
| Study First Received: | February 14, 2012 |
| Last Updated: | June 21, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Merck:
|
Allergies Immunotherapy |
Additional relevant MeSH terms:
|
Conjunctivitis, Allergic Conjunctivitis Conjunctival Diseases Eye Diseases |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013